The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/56074
Title:
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.
Authors:
Cheadle, Eleanor J; Gilham, David E; Hawkins, Robert E
Abstract:
T cells genetically engineered to express tumour-targeting receptors are attractive anti-cancer therapeutic agents. Human T cells engrafted with a chimeric receptor specific for the B-cell lymphoma antigen CD19 fused to the CD3zeta receptor (aCD19z) are functional in vitro. Current successful clinical protocols targeting melanoma use pre-conditioning chemotherapy in combination with T cells. This study demonstrated that interleukin-2 expanded aCD19z T cells combined with cyclophosphamide effectively treated five-day established Raji B-cell lymphoma in an immunocompromised model system with 50% of mice surviving >100 days. This observation strongly supports the combination of antibody targeted T cells with chemotherapy as a novel approach for the therapy of CD19(+) B-cell malignancies.
Affiliation:
Cancer Research UK Department of Medical Oncology, University of Manchester, Manchester, UK.
Citation:
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-Cell lymphoma. 2008, 142 (1):65-8 Br. J. Haematol.
Journal:
British Journal of Haematology
Issue Date:
Jul-2008
URI:
http://hdl.handle.net/10541/56074
DOI:
10.1111/j.1365-2141.2008.07145.x
PubMed ID:
18477047
Type:
Article
Language:
en
ISSN:
1365-2141
Appears in Collections:
All Paterson Institute for Cancer Research; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorCheadle, Eleanor J-
dc.contributor.authorGilham, David E-
dc.contributor.authorHawkins, Robert E-
dc.date.accessioned2009-03-17T17:25:19Z-
dc.date.available2009-03-17T17:25:19Z-
dc.date.issued2008-07-
dc.identifier.citationThe combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-Cell lymphoma. 2008, 142 (1):65-8 Br. J. Haematol.en
dc.identifier.issn1365-2141-
dc.identifier.pmid18477047-
dc.identifier.doi10.1111/j.1365-2141.2008.07145.x-
dc.identifier.urihttp://hdl.handle.net/10541/56074-
dc.description.abstractT cells genetically engineered to express tumour-targeting receptors are attractive anti-cancer therapeutic agents. Human T cells engrafted with a chimeric receptor specific for the B-cell lymphoma antigen CD19 fused to the CD3zeta receptor (aCD19z) are functional in vitro. Current successful clinical protocols targeting melanoma use pre-conditioning chemotherapy in combination with T cells. This study demonstrated that interleukin-2 expanded aCD19z T cells combined with cyclophosphamide effectively treated five-day established Raji B-cell lymphoma in an immunocompromised model system with 50% of mice surviving >100 days. This observation strongly supports the combination of antibody targeted T cells with chemotherapy as a novel approach for the therapy of CD19(+) B-cell malignancies.en
dc.language.isoenen
dc.subjectImmunotherapyen
dc.subjectChimeric Receptoren
dc.subjectAdoptive Transferen
dc.subjectLymphomaen
dc.subjectCyclophosphamideen
dc.subject.meshAnimals-
dc.subject.meshAntigens, CD19-
dc.subject.meshCyclophosphamide-
dc.subject.meshGenetic Engineering-
dc.subject.meshGenetic Vectors-
dc.subject.meshImmunoconjugates-
dc.subject.meshLymphoma, B-Cell-
dc.subject.meshMice-
dc.subject.meshMice, SCID-
dc.subject.meshT-Lymphocytes-
dc.titleThe combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, University of Manchester, Manchester, UK.en
dc.identifier.journalBritish Journal of Haematologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.